Lyra Therapeutics annual meeting results: all proposals approved

Lyra Therapeutics, Inc.

19,500,381 shares present (≈60% of outstanding); quorum met.
Elected Class III directors Palasis (16.4M for), Smith (16.3M for), Tobin (16.6M for).
Ratified BDO USA as independent auditor for FY 2023 (9.5M for, 8K against).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Lyra Therapeutics, Inc. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-13 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-13

Exact text from the filing

Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 9,471,462 8,427 20,492 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Lyra Therapeutics, Inc. shareholders approved Election of three Class III Directors to serve until the Company’s 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. at the 2023-06-13 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-13

Exact text from the filing

NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Maria Palasis, Ph.D. 16,444,471 29,445 2,826,465 W. Bradford Smith 16,337,920 335,996 2,826,465 James R. Tobin 16,638.595 35,321 2,826,465

View on SEC.gov

224 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-028281

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.